Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.77 | N/A | +38.49% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.77 | N/A | +38.49% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed confidence in the company's growth driven by new products. However, they did not provide specific guidance for the upcoming quarters.
Management highlighted strong performance in genetic sequencing.
They emphasized ongoing investments in innovation.
There was no specific guidance provided for future quarters.
Illumina's earnings report showed a strong EPS beat, which indicates better-than-expected profitability. However, the stock reacted negatively, declining by 0.27%. The lack of revenue details and future guidance may have contributed to investor caution.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HALLIBURTON CO